RxDoctor Payments DataLook up a doctor →

Elaine Majerus, MD

Hematology · Saint Louis, MONPI 1326064544

Payments from drug & device makers

$855,415in general payments, 2019–2025

Across 516 payments — averaging $1657.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biomarin Pharmaceutical Inc.$469K
  • Novo Nordisk AS$103K
  • Genentech, Inc.$99K
  • AstraZeneca$70K
  • Novartis$39K
  • Apellis Pharmaceuticals, Inc.$15K
  • plus $61K from 12 others
$18,503in research payments, 2019–2025

Across 5 payments — averaging $3700.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$12K
  • Biomarin Pharmaceutical Inc.$7K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$855,415 in reported general payments places this provider in the 95th percentile of 27 hematology providers in Missouri.

See all hematology providers in Missouri

Medicare billing

Part B allowed, 2024
$477,675
Medicare patients
364
Services billed
16,711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →